Post by holdencf on Mar 5, 2016 20:08:22 GMT -5
finance.yahoo.com/news/tt-034-hepatitis-c-clinical-234200736.html
Benitec is shutting down its Hep C study. Largely due to competitive pressures as a result of new and better drugs on the market. Said they would not be able to generate enough data fast enough to attract a partner.
Pontificates the importance of "first-to-market," status.
They are going to focus on Hep B as their next clinical candidate. IMO they are a minimum of a year away from the clinic, maybe two. Cash is going to be a major issue. They had $17Mn as of June last year. They will probably down to mid-single digits at the end of March (although they only report annually).
They did say, however, that they quite a bit of interest in their Hep B program due to the solid safety profile. My guess is that given that they have nothing in the clinic now, they get acquired.
Benitec is shutting down its Hep C study. Largely due to competitive pressures as a result of new and better drugs on the market. Said they would not be able to generate enough data fast enough to attract a partner.
Pontificates the importance of "first-to-market," status.
They are going to focus on Hep B as their next clinical candidate. IMO they are a minimum of a year away from the clinic, maybe two. Cash is going to be a major issue. They had $17Mn as of June last year. They will probably down to mid-single digits at the end of March (although they only report annually).
They did say, however, that they quite a bit of interest in their Hep B program due to the solid safety profile. My guess is that given that they have nothing in the clinic now, they get acquired.